Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
Portfolio Pulse from
Vaxart announced a favorable review from the Independent Data Safety Monitoring Board (DSMB) for its COVID-19 Phase 2b clinical trial. The DSMB recommended the study proceed without modifications after assessing the initial safety data from 400 participants over 30 days.
January 14, 2025 | 1:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxart received a positive safety review from the DSMB for its COVID-19 Phase 2b trial, allowing the study to continue without modifications.
The DSMB's recommendation to proceed without modifications is a positive indicator of the trial's safety profile, which could boost investor confidence and positively impact Vaxart's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100